Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Francesco Zaja

Showing results (31-40 of 145) with videos related to

Pageof 15
Sort By:
Haematologica|February 12, 2002
B-cell depletion with rituximab as treatment for immune hemolytic anemia and chronic thrombocytopeniaFrancesco Zaja, Isabella Iacona, Paola Masolini, et al.
American Journal of Hematology|January 24, 2024
An unusual form of BRAF-V600E mutated hairy cell neoplasm with clinical resistance to BRAF inhibition: Challenging precision medicineAndrea Marra, Alessia Santi, Alessandra Pucciarini, et al.
Mediterranean Journal of Hematology and Infectious Diseases|May 19, 2021
Practical Recommendations for the Management of Patients with ITP During the COVID-19 PandemicFrancesco Rodeghiero, Silvia Cantoni, Giuseppe Carli, et al.
Annals of Hematology|May 28, 2026
Daratumumab in combination with GDP chemotherapy in CD38-positive relapsed/refractory peripheral T-cell lymphoma: a phase 2 study of the Fondazione Italiana LinfomiMario Ballerini, Elisa Lucchini, Emanuele Ravano, et al.
Experimental Hematology|March 18, 2006
The development of autoantibodies after allogeneic stem cell transplantation is related with chronic graft-vs-host disease and immune recoveryFrancesca Patriarca, Cristina Skert, Alessandra Sperotto, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 13, 2013
Combination of rituximab, bendamustine, and cytarabine for patients with mantle-cell non-Hodgkin lymphoma ineligible for intensive regimens or autologous transplantationCarlo Visco, Silvia Finotto, Renato Zambello, et al.
Haematologica|December 23, 2003
Fludarabine + prednisone +/- alpha-interferon followed or not by alpha-interferon maintenance therapy for previously untreated patients with chronic lymphocytic leukemia: long term results of a randomized studyFrancesca R Mauro, Pierluigi Zinzani, Francesco Zaja, et al.
Haematologica|September 8, 2006
Effect on survival of the development of late-onset non-infectious pulmonary complications after stem cell transplantationFrancesca Patriarca, Cristina Skert, Francesca Bonifazi, et al.
Blood|January 24, 2012
Low-dose rituximab in adult patients with idiopathic autoimmune hemolytic anemia: clinical efficacy and biologic studiesWilma Barcellini, Francesco Zaja, Anna Zaninoni, et al.
Hematology Reports|July 5, 2021
Immune checkpoint inhibitors in combination with radiotherapy as salvage treatment for relapsed/refractory classical Hodgkin lymphoma: A retrospective analysis in 12 patientsElisa Lucchini, Chiara Rusconi, Mario Levis, et al.
Pageof 15

Showing results (31-40 of 145) with videos related to

Sort By:
Pageof 15
Haematologica|February 12, 2002
B-cell depletion with rituximab as treatment for immune hemolytic anemia and chronic thrombocytopeniaFrancesco Zaja, Isabella Iacona, Paola Masolini, et al.
American Journal of Hematology|January 24, 2024
An unusual form of BRAF-V600E mutated hairy cell neoplasm with clinical resistance to BRAF inhibition: Challenging precision medicineAndrea Marra, Alessia Santi, Alessandra Pucciarini, et al.
Mediterranean Journal of Hematology and Infectious Diseases|May 19, 2021
Practical Recommendations for the Management of Patients with ITP During the COVID-19 PandemicFrancesco Rodeghiero, Silvia Cantoni, Giuseppe Carli, et al.
Annals of Hematology|May 28, 2026
Daratumumab in combination with GDP chemotherapy in CD38-positive relapsed/refractory peripheral T-cell lymphoma: a phase 2 study of the Fondazione Italiana LinfomiMario Ballerini, Elisa Lucchini, Emanuele Ravano, et al.
Experimental Hematology|March 18, 2006
The development of autoantibodies after allogeneic stem cell transplantation is related with chronic graft-vs-host disease and immune recoveryFrancesca Patriarca, Cristina Skert, Alessandra Sperotto, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 13, 2013
Combination of rituximab, bendamustine, and cytarabine for patients with mantle-cell non-Hodgkin lymphoma ineligible for intensive regimens or autologous transplantationCarlo Visco, Silvia Finotto, Renato Zambello, et al.
Haematologica|December 23, 2003
Fludarabine + prednisone +/- alpha-interferon followed or not by alpha-interferon maintenance therapy for previously untreated patients with chronic lymphocytic leukemia: long term results of a randomized studyFrancesca R Mauro, Pierluigi Zinzani, Francesco Zaja, et al.
Haematologica|September 8, 2006
Effect on survival of the development of late-onset non-infectious pulmonary complications after stem cell transplantationFrancesca Patriarca, Cristina Skert, Francesca Bonifazi, et al.
Blood|January 24, 2012
Low-dose rituximab in adult patients with idiopathic autoimmune hemolytic anemia: clinical efficacy and biologic studiesWilma Barcellini, Francesco Zaja, Anna Zaninoni, et al.
Hematology Reports|July 5, 2021
Immune checkpoint inhibitors in combination with radiotherapy as salvage treatment for relapsed/refractory classical Hodgkin lymphoma: A retrospective analysis in 12 patientsElisa Lucchini, Chiara Rusconi, Mario Levis, et al.
Pageof 15